Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro

Breast Cancer Research and Treatment

Volumn 56, Issue 1, 1999, Pages 79-90

  Kano, Yasuhiko ^a   Akutsu, Miyuki ^a   Suzuki, Kenichi ^a   Ando, Jiro ^a   Tsunoda, Saburo ^a  

^a TOCHIGI CANCER CENTER   (Japan)

Author keywords

Drug combination; Isobologram; Paclitaxel; Vinorelbine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; NAVELBINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0032830815     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006254315174     Document Type: Article

References (54)

1. Bender RA, Hamel E, Hande KR: Plant alkaloids. In: Chabner BA, Collins JM (eds) Cancer Chemotherapy: principle and practice. Lippincott Philadelphia, 1992, pp 253-275
2. Mangeney P, Andriamialisoa RZ, Langlois N, Langlois Y, Potier PA.: New class of antitumor compounds: 5′-nor and 5′,6′-secoderivatives of vinblastine-type alkaloids. J Org Chem 44: 3755-3768, 1979
3. Maral R, Bourut C, Chenu E, Maine G: Experimental in vivo cross-resistance of vinca alkaloid drugs. Cancer Chemother. Pharmacol 5: 197-199, 1981
4. Maral R, Bourut C, Chenu E, Mathe G: Experimental antitumor activity of 5′-nor anhydrovinblastine navelbine. Cancer Lett 22: 49-54, 1984
5. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP, Krikorian A: Experimental antitumor activity of Navelbine. Semin Oncol 16(suppl 4): 15-20, 1989
6. Binet S, Fellous A, Lataste H, Krikorian A, Couzinier JP, Meininger V: In situ analysis of the action of navelbine on various types of microtubules using immunofluorescence. Sem Oncol 16 (suppl 4): 5-8, 1989
7. Besenval M, Delgado M, Demarez JP, Krikorian A: Safety and tolerance of navelbine in phase I II clinical studies. Semin Oncol 16 (suppl 4): 37-40, 1989
8. Depierre A, Lemarie E, Dudouis G, Gamier G, Jacoulet P, Dalphin JC: A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14: 115-119, 1991
9. Canobbio L, Boccardo F, Pastorino G, Brema F, Martini C, Resasco M, Santi L: Phase-II study of navelbine in advances breast cancer. Semin Oncol 16 (suppl 4): 33-36, 1989
10. George MJ, Heron JF, Kerbrat P, Chauvergne J, Goupil A, Lebrun D, Guastalla JP, Namer M, Bugat R, Ayme Y, Toussaint C, Lhomme C: Navelbine in advanced ovarian epitherial cancer: a study of the French Oncology Centers. Semin Oncol 16 (suppl 4): 30-32, 1989
11. Wani MC, Taylor HL, Wall ME, Coggen P, Mcphail AT: Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and agents from Taxus brevifolia. Am Chem Soc 93: 2325-2327, 1971
12. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667, 1979
13. Kumar N: Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 256: 10435-10441, 1981
14. Schiff PB, Horwitz SB: Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule-associated proteins. Biochemistry 20: 3247-5152, 1981
15. Grem JL, Tutsch KD, Simon KJ, Alberti DB, Willson JKV, Tormey DC, Swaminathan S, Trump DL: Phase I study of taxol administered as a short i.v. infusion daily for 5 days. Cancer Treat Rep 71: 1179-1184, 1987
16. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS: Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 71: 1171-1177, 1987
17. Wiernik PH, Schwartz EL, Eizig A, Straumann JJ, Lipton RB, Dutcher JP: Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma. J Clin Oncol 5: 1232-1239, 1987
18. Donehower RC, Rowinsky EK: An overview of experience with taxol (paclitaxel) in the USA. Cancer Treat Rev 19 (suppl. C): 63-78, 1993
19. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, Donehower RC: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111: 273-279, 1989
20. Holmes FA, Walters RS, Theriault RL, Forman AD, Newton LK, Raber MN, Buzdar AU, Frye DK, Hortobagyi GN: Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83: 1797-1805, 1991
21. Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes E, Gross MM, Enrique D, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK: Phase II study of taxol in untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993
22. Bissery MC, Guenard D, Gueritte-Voegelein F, Lavelle F: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852, 1991
23. Adams DJ: Synergy of navelbine-taxol combination treatment in two human breast cancer cell lines. Proc Am Assoc Can Res 35: 327, 1994 (abstract)
24. Gomi K, Ashizawa T, Asada M, Sugiyama K, Okabe M: Studies on KW2307 (navelbine). vii. Combination effects of KW-2307 with taxol against murine and human tumors in vitro and in vivo. Proc Jap Can Assoc 54: 619, 1995 (abstract)
25. Knick VC, Eberwein DJ, Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 19; 87: 1072-1077, 1995
26. Budman DR, Stiel CA, Kreis W: In vitro studies of paclitaxel in combination with either etoposide or vinorelbine: sequence dependent effects causing synergism and antagonism. Proc Am Assoc Can Res 37: 365, 1906 (abstract)
27. Photiou A, Shah P, Leong LK, Moss J, Retsas S: In vitro synergy of paclitaxel and vinorelbine against human melanoma cell lines. Eur J Cancer 33: 463-470, 1997
28. Culiner S, Roch I, Pinguet F: Combination paclitaxel and vinorelbine therapy: in vitro cytotoxic interactions and dose-escalation study in patients with anthracycline-resistant metastatic breast cancer. Proc Am Soc Clin Oncol 17: 135a, 1998 (abstract)
29. Giannakakou P, Villalba L, Li H, Poruchynsky M, Fojo T: Combination of paclitaxel and vinblastine and their effects on tubulin polymerization and cellular cytotoxicity: characterization of a synergistic schedule. Int J Cancer 75: 57-63, 1998
30. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 22 (2 Suppl 5): 66-70, 1995
31. Chang AY, DeVore R, Johnson D: Pilot study of vinorelbine (navelbine) and paclitaxel in patients with refractory non-small cell lung cancer. Semin Oncol 23 (2 Suppl 5): 19-21, 1996
32. Michelotti A, Gennari A, Salvadori B, Giannessi PG, Baldini E, Tibaldi C, Da Prato M, Conte PF: Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 23 (5 Suppl 11): 38-40, 1996
33. Parimoo D, Jeffers S, Muggia FM: Severe neurotoxicity from vinorelbine-paclitaxel combinations J Natl Cancer Inst 88: 1079-1080, 1996
34. Retsas S, Mohith A, Mackenzie H: Taxol and vinorelbine: a new active combination for disseminated malignant melanoma. Anticancer Drugs 7: 161-165, 1996
35. Iaffaioli RV, Facchini G, Tortoriello A, Caponigro F, Illiano A, Gentile M, Gravina A, Muto P: Phase I study of vinorelbine and paclitaxel in small-cell lung cancer. Cancer Chemother Pharmacol 41: 86-90, 1997
36. Romero Acuna L, Langhi M, Perez J, Leone B, Machiavelli M, Lacava J, Vallejo C, Romero A, Cuevas J, Ortiz E, Grasso S, Amato M, Salvadori M, Rodriguez R, Barbieri M, Romero Acuna J: Grupo Oncologico Cooperative del Sur (GOCS). Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. Proc Am Soc Clin Oncol 16: 661, 1997 (abstract)
37. Vici P, Amodio A, Di Lauro L, Paolettei G, Foggi P, Squilloni E, Gionfra T, Conti F, Lopez M: Simultaneous infusion of vinorelbine and paclitaxel in advanced breast cancer. Am Soc Clin Oncol 16: 688, 1997 (abstract)
38. Cocconi G, Mambrini A, Vasini G, Quarta MC, Bella M, Gentile A, Di Sarra S: Vinorelbine combined with paclitaxel, administered in a continuous 96-hour iv infusion, in pretreated advanced breast cancer patients. Proc Am Soc Clin Oncol 17: 208a, 1998 (abstract)
39. Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingstone RB: Paclitaxel/vinorelbine chemotherapy with concurrent for metastatic breast cancer: phase I-II study in doxorubicin-treated patients. Proc Am Soc Clin Oncol 17: 139a, 1998 (abstract)
40. Gardin G, Pronzato P, Tognoni A, Vigani A, Vaira F, Gasco M, D'Amico M, Vecchio S, Antonelli G, Banfi A, Queirolo P, Campora E, Sertoli MR: A phase II trial of vinorelbine and Paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline containing chemothorapy. Proc Am Soc Clin Oncol 17: 142a, 1998 (abstract)
41. Willey J, Ibrahim NK, Walters R, Rahman Z, Valero V, Esteva FJ, Hortobagyi GN: Vocal cord paralysis secondary to biweekly vinorelbine and paclitaxel by simultaneous 3-hour infusion with G-CSF support as a frontline therapy for metastatic breast cancer patients. Proc Am Soc Clin Oncol 17: 183a, 1998 (abstract)
42. Martin M, Casado A, Perez Segura P, Garcia Carbonero I, Diaz Rubio E: Paclitaxel plus vinorelbine in metastatic breast Cancer patients with contraindications to receive anthracyclines. Oncology Huntingt. 12(1 Suppl 1): 28-30, 1998
43. Tortoriello A, Facchini G, Caponigro F, Santangelo M, Benassai G, Persico G, Citarella A, Carola M, Marzano N, Laffaioli RV: Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer. Breast Cancer Res Treat 47: 91-97, 1998
44. Steel GG, Peckham MJ: Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radial Oncol Biol Phys 5: 85-93, 1979
45. Kano Y, Sakamoto S, Kasahara T, Akutsu M, Inoue Y, Miura Y: In vitro effects of amsacrine: in combination with other anticancer agents. Leukemia Res 15: 1059-1064, 1991
46. Rideout DC, Chou TC: Synergism, antagonism, and potentiation of chemotherapy. In: Chou TC und Rideout DC, (eds) Synergism and Antagonism in Chemotherapy. San Diego: Academic Press: 3-60, 1991
47. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1988
48. Greco WR, Bravo G, Parsons JC: The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 47: 331-385, 1995
49. Frey CM: Role of modelling in joint action studies. J Natl Cancer Inst 86: 1493-1495, 1994
50. Kano Y, Ohnuma T, Okano T, Holland JF: Effects of vincristine in combination with methotrexate and other antitumor agents in human acute lymphoblastic leukemia cells in culture. Cancer Res 48: 351-356, 1988
51. Kano Y, Suzuki K, Akutsu M, Suda k, Inoue Y, Yoshida M, Sakamoto S, Miura Y: Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50: 604-610, 1992
52. Kano Y, Akutsu M, Tsunoda S, Suzuki K, Adachi K: In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines. Cancer Chemother Pharmacol 42: 91-98, 1998
53. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G: Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 42: 545-547, 1992
54. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190, 1995